These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 28343447)
1. The undifferentiated carcinoma that became a melanoma: Re-biopsy of a cancer of an unknown primary site: a case report. Røe OD; Wahl SG J Med Case Rep; 2017 Mar; 11(1):82. PubMed ID: 28343447 [TBL] [Abstract][Full Text] [Related]
2. Undifferentiated Sarcoma as Intermediate Step in Rhabdomyosarcomatous Transformation of a Metastatic Malignant Melanoma Resistant to Anti-BRAF Therapy: A Phenomenon Associated With Significant Diagnostic and Therapeutic Pitfalls. Tran TAN Int J Surg Pathol; 2019 Sep; 27(6):669-677. PubMed ID: 30942107 [TBL] [Abstract][Full Text] [Related]
3. Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report. Casadevall D; Vidal J; Gallardo F; Zuccarino F; Arumí-Uría M; Dalmases A; Bellosillo B; Montagut C J Med Case Rep; 2016 Jun; 10(1):158. PubMed ID: 27255157 [TBL] [Abstract][Full Text] [Related]
4. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514 [TBL] [Abstract][Full Text] [Related]
5. Diagnostic dilemma: late presentation of amelanotic BRAF-negative metastatic malignant melanoma resembling clear cell sarcoma: a case report. Wagner BP; Epperla N; Medina-Flores R Diagn Pathol; 2013 Nov; 8():192. PubMed ID: 24274261 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250 [TBL] [Abstract][Full Text] [Related]
7. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505 [TBL] [Abstract][Full Text] [Related]
8. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients. Sanmamed MF; Fernández-Landázuri S; Rodríguez C; Lozano MD; Echeveste JI; Pérez Gracia JL; Alegre E; Carranza O; Zubiri L; Martín-Algarra S; González A Clin Chim Acta; 2014 Feb; 429():168-74. PubMed ID: 24333389 [TBL] [Abstract][Full Text] [Related]
9. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient. Peters S; Bouchaab H; Zimmerman S; Bucher M; Gaide O; Letovanec I; Homicsko K; Michielin O Melanoma Res; 2014 Oct; 24(5):496-500. PubMed ID: 25185693 [TBL] [Abstract][Full Text] [Related]
10. Advances in the management of melanoma: targeted therapy, immunotherapy and future directions. Dean E; Lorigan P Expert Rev Anticancer Ther; 2012 Nov; 12(11):1437-48. PubMed ID: 23249108 [TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930 [TBL] [Abstract][Full Text] [Related]
12. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Ravnan MC; Matalka MS Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884 [TBL] [Abstract][Full Text] [Related]
13. Intramammary metastatic melanoma of unknown primary origin in a 58-year old patient: a case report. El-Tani Z; Duc C; Gluecker T; Cottier O J Med Case Rep; 2016 Dec; 10(1):363. PubMed ID: 27998306 [TBL] [Abstract][Full Text] [Related]
14. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge]. Capovilla M Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719 [TBL] [Abstract][Full Text] [Related]
15. Upcoming strategies for the treatment of metastatic melanoma. Spagnolo F; Queirolo P Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184 [TBL] [Abstract][Full Text] [Related]
16. Folliculotropic Cutaneous Metastases and Lymphangitis Carcinomatosa: When Cutaneous Metastases of Breast Carcinoma Are Mistaken for Cutaneous Infections. Paolino G; Panetta C; Didona D; Donati M; Donati P Acta Dermatovenerol Croat; 2016 Jun; 24(2):154-7. PubMed ID: 27477179 [TBL] [Abstract][Full Text] [Related]
17. Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib. Starz H; Gutschi M; Welzel J; Haas C J Dtsch Dermatol Ges; 2014 Feb; 12(2):151-4. PubMed ID: 24238398 [No Abstract] [Full Text] [Related]
18. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. Ascierto PA; Simeone E; Sileni VC; Del Vecchio M; Marchetti P; Cappellini GC; Ridolfi R; de Rosa F; Cognetti F; Ferraresi V; Testori A; Queirolo P; Bernengo MG; Guida M; Galli L; Mandalà M; Cimminiello C; Rinaldi G; Carnevale-Schianca F; Maio M Cancer Invest; 2014 May; 32(4):144-9. PubMed ID: 24484235 [TBL] [Abstract][Full Text] [Related]
19. Multiple BRAF Wild-Type Melanomas During Dabrafenib Treatment for Metastatic BRAF-Mutant Melanoma. Carrera C; Puig-Butillè JA; Tell-Marti G; García A; Badenas C; Alós L; Puig S; Malvehy J JAMA Dermatol; 2015 May; 151(5):544-8. PubMed ID: 25651238 [TBL] [Abstract][Full Text] [Related]
20. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]